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Abstract
The most common interventions in structural heart diseases for various age groups are percu-
taneous occlusions of septal defects. We present the case of a woman with patent foramen ovale
(PFO) periodically causing a right-to-left shunt, after an incident of stroke, with migraine
attacks, treated by percutaneous closure of PFO with use of a novel occluder device — an
Occlutech Figulla®. The procedure was performed under X-ray and transesophageal
echocardiographic monitoring. The novel Occlutech device described above features easy ma-
nipulation, good safety and some constructional innovations that enable the time of antiplatelet
prophylaxis to be shortened, thus potentially minimizing procedure related risk. (Cardiol J
2008; 15: 380–383)
Key words: patent foramen ovale, percutaneous devices
Introduction
The most common interventions in structural
heart diseases in various age groups are percuta-
neous occlusions of septum defects [1]. We present
the case of woman with patent foramen ovale (PFO)
periodically causing a right-to-left shunt, after an
incident of stroke, with migraine attacks, treated by
percutaneous closure of PFO with use of a novel
occluder device — an Occlutech Figulla® (Fig. 1).
To the best of the authors’ knowledge, there are
no previous publications in MEDLINE reporting the
use of this device for PFO occlusion.
Case report
The patient was a professionally active 41-year-
-old woman, 1 year after a minor stroke with clinical
presentation of right hemiparesis, suffering from Figure 1. Occlutech Figulla® PFO Occluder.
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typical migraine attacks with aura. She was admit-
ted to our Department, in stable condition, to opti-
mize her treatment. Echocardiography demonstra-
ted a patent foramen ovale with right-to-left shunt
during a Valsalva test, without signs of right atrial
overload (right atrial diameter in diastole in four
chamber view: 35 mm). In order to precisely visu-
alize PFO morphology and to exclude atrial throm-
bus and other contraindications to percutaneous
closure of PFO, we performed transesophageal
echocardiography showing a 4 mm maximal diame-
ter of PFO tunnel. A novel device, an Occlutech
Figulla® PFO Occluder, was chosen.
The procedure was performed under X-ray and
transesophageal echocardiographic monitoring with
premedication of midazolam iv. (up to 8 mg total).
One day before the procedure the patient received
325 mg acetylsalicylic acid and 75 mg clopidogrel,
in a catheterization laboratory, just before proce-
dure 5000 U unfractionated heparin (activated co-
agulation time — ACT 220 s). After placement of
the right femoral vein sheath, a guidewire was ad-
vanced into the left atrium through the open fora-
men ovale and positioned in the upper left pulmo-
nary vein, followed by insertion of a Mullins
12 French catheter under transesophageal echocardio-
graphic monitoring. The device was introduced
through the catheter and the left atrial disc was
released by pushing it out on the left atrial side.
Withdrawal of the Mullins sheath allowed the release
of the right atrial disc (analogous to the technique use
for Amplatz occluder implantation) (Fig. 2–4). The
correct position and complete PFO closure was
seen in transesophageal echocardiography. On the
next day the correct position of the occluder without
residual flow was confirmed in control transthora-
cic echocardiography (Fig. 5, 6). The patient was
Figure 2. Freeing of right disk PFO Occluder device
with transesophageal echocardiography and radiolo-
gical monitoring (projection AP).
Figure 3. Fixation of Figulla® PFO Occluder with transe-
sophageal echocardiography and radiological monito-
ring (projection RAO 10).
Figure 4. Figulla® PFO Occluder after implantation pro-
cedure (projection LAO 30 — arrow).
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discharged with the following medical recommen-
dations: 75 mg clopidogrel for 3 months, 100 mg
acetylsalicylic acid for 6 months and 12 months stan-
Figure 6. Transthoracic echocardiography 3D in real time. Right atrial view showing a right disk of the implant with
characteristic protuberance of the delivery channel.
Figure 5. Transthoracic echocardiography. Modified parasternal short axis view. Figulla® PFO Occluder after implan-
tation procedure (arrow); LA — left atrium, RA — right atrium.
dard antibiotic prophylaxis for endocarditis (before
possible dental, gastroenterological and gynecolo-
gical procedures).
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Discussion
Patent foramen ovale, the remnant of fetal cir-
culation, is a common finding present in 25% of the
population [2]. A relationship between PFO and
several clinical conditions, such as stroke, migra-
ine, platypnea-orthodeoxia syndrome, neurological
decompression illness in divers, high altitude pul-
monary oedema and economy class syndrome, have
been documented [3, 4]. The morphology of PFO
is various and dependent on the age of the patient.
PFO images, obtained from the echocardiography,
enable a PFO classification to be made based on the
diameter, length of tunnel and concomitant patho-
logies of the interatrial septum [5]. Given the large
number of asymptomatic subjects, no standard pre-
ventive therapy is currently recommended. The
best treatment modality to prevent recurrent stro-
ke in patients with PFO has not been defined [6].
Interventional closure of the PFO has become
a promising alternative for lifelong antiplatelet or
anticoagulant therapies. Observational non-rando-
mized studies have shown percutaneous PFO clo-
sure to be more effective than medical treatment
for stroke prevention, in particular in patients with
complete closure, as well as in patients with cere-
brovascular events at baseline [7].
The Figulla® PFO Occluder is a recently regi-
stered implant type, made up of two nitinol disks,
intended for the closure of a persisting foramen
ovale. Construction and implantation procedure are
analogous to an Amplatz® Occluder. However, the-
re are some important structural innovations, en-
couraging the use of the novel device for PFO clo-
sure. An atraumatic tip, increased flexibility and
minimizing the amount of material implanted (25%
less material in the left atrium, 50% less with the
single disc PFO device) make the Figulla® PFO
Occluder safer and more comfortable during implan-
tation than other devices. Additionally, the Figul-
la® PFO Occluder inflicts less risk of “ballooning”,
and the increased flexibility of discs offers optimi-
zed adherence to the septum and left atrial wall.
Faster endothelization reduces the time of antipla-
telet prophylaxis with clopidogrel to 3 months.
Conclusions
Contemporary techniques of percutaneous clo-
sure of interatrial septum defects allow the indivi-
dualization of device choice. The novel Occlutech
device described above features easy manipulation,
good safety and some constructional innovations
that enable the time of antiplatelet prophylaxis to
be shortened thus potentially minimizing procedu-
re related risks.
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